Skip to main content
OpenTrials
Completed

NCT Number: NCT06004583

C-Reactive Protein/Albumin Ratio and Acne Vulgaris

Objective: Acne vulgaris, an inflammatory disease, was investigated in this study with the claim that C-reactive protein (CRP) / albumin ratio and some hematological parameter ratios have the potential to be used as inflammatory markers to monitor disease severity and prognosis.

Methods: A descriptive cross-sectional study was conducted with two groups of patients aged 18-65 years, 61 patients diagnosed with acne vulgaris and 35 healthy control patients, and routine hemogram and biochemical parameters were compared. The Global Acne Severity Index was used to determine the severity of acne vulgaris.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acne Vulgaris Acneiform Eruptions Sebaceous Gland Diseases Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Observational

Primary location

AtaturkU

Erzurum, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Acne vulgaris patients diagnosed by a dermatologist
  • Healthy participants without acne
  • 18-40 years of age
  • Voluntary participation

Exclusion criteria

  • Aged below18 or above 40 years
  • Not voluntarily participated patents
  • Pregnants, breast milked mothers, emergency situations

Treatment and study plan

Biochemical blood analysis

Diagnostic Test

Serum CRP and albumin levels

Primary outcomes

  1. CRP/albumin ratio

    Time frame: 3 months

    Statistical difference between groups

Secondary outcomes

  1. Usage of CRP/albumin ratio as a Biomarker

    Time frame: 3 months

    New detection of CRP/albumin ratio as a new biomarker in the Acne patients

Sponsors and collaborators

Lead sponsor

Ataturk University

Other

Registry information

Official study title

Relationships Between Disease Severity and The C-Reactive Protein/Albumin Ratio and Various Hematological Parameters in Patients With Acne Vulgaris

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Aug 22, 2023
Registry last updated
Aug 22, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.